Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021333 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
A Phase 2 study of Lung Cancer and Head and Neck Cancer, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 18
- Study locations
NCT00021333: Completed Phase 2 study of Lung Cancer and Head and Neck Cancer, sponsored by Fox Chase Cancer Center.
NCT00021333 is a Phase 2 study of Lung Cancer and Head and Neck Cancer that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 29 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 18 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021333, a Phase 2 study of Lung Cancer and Head and Neck Cancer, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 18
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase II trial to study the effectiveness of paclitaxel and cisplatin plus radiation therapy followed by filgrastim in treating patients who have recurrent head and neck cancer or lung cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- RADIATION radiation therapy
- BIOLOGICAL filgrastim
Study Locations (18)
Pennsylvania
- Bon Secours-Holy Family Health System - Altoona
- Delaware County Memorial Hospital - Drexel Hill
- Pinnacle Health Hospitals - Harrisburg
- Conemaugh Memorial Hospital - Johnstown
- Saint Mary Regional Center - Langhorne
- Central Montgomery Medical Center - Lansdale
- Paoli Memorial Hospital - Paoli
- Fox Chase Cancer Center - Philadelphia
- Pottstown Memorial Regional Cancer Center - Pottstown
- Reading Hospital and Medical Center - Reading
- Southern Chester County Medical Center - West Grove
New Jersey
- Hunterdon Regional Cancer Center - Flemington
- Kimball Medical Center - Lakewood
- South Jersey Regional Cancer Center - Millville
- Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County - Mount Holly
- Riverview Medical Center - Booker Cancer Center - Red Bank
- Community Medical Center - Toms River
- St. Francis Medical Center - Trenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 1999-09 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
What the finished NCT00021333 record still lists
NCT00021333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.
NCT00021333 lists 18 locations in 2 states (Pennsylvania, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00021333 about?
NCT00021333 is a clinical study titled "Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may make tumor cells more sensitive to radiation therapy. PURPOSE: P...
What is the current status of trial NCT00021333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 1999-09. Estimated completion is 2008-05.
What conditions does trial NCT00021333 study?
This clinical trial studies the following conditions: Lung Cancer, Head and Neck Cancer.
What interventions are being tested in trial NCT00021333?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00021333?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00021333 being conducted?
This trial has 18 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00021333's enrollment target sits among peer trials
29 331st of 409 higher than 78 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia